Metabolik sindrom va ichak disbiozi bo'lgan bemorlarda yuz-jagʻ flegmonalarini davolash strategiyalarini optimallashtirish

The objective of the article is to assess the efficacy of a comprehensive therapeutic approach incorporating microbiota correction and metabolic stabilization in patients with maxillofacial (MFR) phlegmons complicated by metabolic syndrome (MS) and intestinal dysbiosis. Materials and Methods: A prospective randomized study involved 80 patients ($n=80$) with MFR phlegmons. All participants exhibited MS and Grade II-III dysbiosis. The study group ($n=40$) received standard surgical care plus synbiotics, alpha-lipoic acid, and intensive glycemic control. The control group ($n=40$) received standard care only. Key metrics included LII, C-reactive protein (CRP), and wound healing duration. Results: Patients in the study group demonstrated faster clinical recovery. By day 5, the LII decreased to $1.5 \pm 0.1$ vs. $2.8 \pm 0.2$ in the control group ($p < 0.01$). Wound cleansing was accelerated by $2.4 \pm 0.5$ days. Conclusion: Addressing the gut-metabolic axis is essential for improving surgical outcomes in comorbid patients with MFR infections.

Hali tarjima qilinmagan